📣 VC round data is live. Check it out!

Immuneering Valuation Multiples

Discover revenue and EBITDA valuation multiples for Immuneering and similar public comparables like Oryzon Genomics, Panacea Biotec, Prelude Therapeutics, IMBiologics and more.

Immuneering Overview

About Immuneering

Immuneering Corp is a biopharmaceutical company. It is focused on improving patient outcomes across a spectrum of debilitating oncologic and neurologic diseases by applying deep knowledge of translational bioinformatics to every stage of the drug development process. The company's proprietary computational Disease Cancelling Technology platform enables Immuneering's drug discovery programs. The company also provides unparalleled computational biology capabilities to pharmaceutical and biotechnology companies.


Founded

2008

HQ

United States

Employees

66

Financials (LTM)

Revenue: -
Net Income: ($65M)

EV

$124M

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

Immuneering Financials

Immuneering reported last 12-month revenue of -.

In the same LTM period, Immuneering generated - in gross profit and had net loss of ($65M).

Revenue (LTM)


Immuneering P&L

In the most recent fiscal year, Immuneering reported revenue of - and EBITDA of ($59M).

Immuneering is unprofitable as of last fiscal year, with EBITDA margin of - and net margin of -.

See analyst estimates for Immuneering
LTMLast FY202320242025202620272028
EBITDA-($59M)($58M)($64M)($59M)
Net Profit($65M)($56M)($53M)($61M)($56M)

Financial data powered by Morningstar, Inc.

Immuneering Stock Performance

Immuneering has current market cap of $277M, and enterprise value of $124M.

Market Cap Evolution


Immuneering's stock price is $4.28.

Immuneering share price decreased by 26.0% in the last 30 days, and increased by 27.0% in the last year.

Immuneering has an EPS (earnings per share) of $-0.87.

See more trading valuation data for Immuneering
EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$124M$277M-4.8%-26.0%-18.8%27.0%$-0.87

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

Immuneering Valuation Multiples

Immuneering trades at (2.1x) EV/EBITDA.

See NTM and 2027E valuation multiples for Immuneering

EV / Revenue (LTM)


Immuneering Financial Valuation Multiples

As of June 3, 2026, Immuneering has market cap of $277M and EV of $124M.

Immuneering has a P/E ratio of (4.3x).

LTMLast FY202320242025202620272028
EV/EBITDA-(2.1x)(2.1x)(1.9x)(2.1x)
EV/EBIT(1.8x)(2.1x)(2.1x)(1.9x)(2.1x)
P/E(4.3x)(4.9x)(5.2x)(4.5x)(4.9x)
EV/FCF-(2.7x)(2.5x)(2.3x)(2.7x)

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified Immuneering Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

Immuneering Margins & Growth Rates

Immuneering grew net profit by 38% in the last fiscal year.

See estimated margins and future growth rates for Immuneering

Immuneering Growth Rates

FY+1/FY23/2424/2525/2626/2727/2828/29
EBITDA Growth-10%(7%)-
EBIT Growth39%10%(7%)39%
Net Profit Growth38%14%(8%)38%
FCF Growth-12%(17%)-

Data powered by FactSet, Inc. and Morningstar, Inc.

Immuneering Operational KPIs

Immuneering's revenue per employee in the last FY averaged $0.0M, while opex per employee averaged $0.9M for the same period.

Access forward-looking KPIs for Immuneering
Last FY202620272028
Revenue per Employee$0.0M
Opex per Employee$0.9M

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

Immuneering Competitors

Immuneering competitors include Oryzon Genomics, Panacea Biotec, Prelude Therapeutics, IMBiologics, Santhera Pharma, Zentalis Pharma, Eledon Pharmaceuticals, Surrozen, SAB Bio and Organogenesis.

Most Immuneering public comparables operate across Biopharmaceuticals, BioTech and DeepTech.

EV/RevenueEV/EBITDA
Last FYLTM2027ELast FYLTM2027E
Oryzon Genomics-78.6x(44.4x)(25.5x)
Panacea Biotec3.9x-79.5x-
Prelude Therapeutics17.8x11.3x(2.1x)(2.0x)
IMBiologics-27.6x--
Santhera Pharma3.2x2.9x(7.8x)(11.9x)
Zentalis Pharma--(0.7x)(0.7x)
Eledon Pharmaceuticals--(2.0x)-
Surrozen48.5x35.8x(4.1x)-

This data is available for Pro users. Sign up to see all Immuneering competitors and their valuation data.

Start Free Trial

Immuneering VC Funding History

Before going public, Immuneering raised $82M in total equity funding, across 2 rounds.


Immuneering Funding Rounds

DateStageRaised FromRaisedValuationRev. MultipleDeal Summary
Jan-21Series BCormorant Asset Management; Rock Springs Capital; Surveyor Capital$62M-Immuneering Corporation, a Cambridge, Massachusetts-based biotech company, completed an oversubscribed $62 million Series B financing on January 5, 2021, led by Cormorant Asset Management, with participation from Surveyor Capital (a Citadel company), Rock Springs Capital, funds advised by T. Rowe Price Associates, BlackRock, Perceptive Advisors, LYFE Capital, existing investors, and senior management. The proceeds are designated to advance clinical-stage programs targeting the RAS/MAPK pathway in various tumor types and cancers, progress additional programs in neuroscience and immuno-oncology, develop its Disease Cancelling Technology (DCT) platform, and enhance its computational biology services business. The lead program, IMM-1-104, a MEK inhibitor, is highlighted for its potential to provide deep pathway suppression with improved tolerability compared to existing MEK inhibitors. Immuneering's DCT platform generates insights into therapies offering differentiated efficacy and safety, particularly for cancers driven by RAS/MAPK alterations. The company also operates a computational biology services arm, collaborating with large pharma on optimizing existing medicines through patient stratification, combination strategies, and mechanism elucidation. CEO Ben Zeskind emphasized the platform's role in advancing the company to clinical stages, while Cormorant managing director Andrew Phillips noted the urgent need for better MAPK-targeted treatments.
Jan-20Series ABoxcar Capital Partners$20M--

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About Immuneering

When was Immuneering founded?Immuneering was founded in 2008.
Where is Immuneering headquartered?Immuneering is headquartered in United States.
How many employees does Immuneering have?As of today, Immuneering has over 66 employees.
Who is the CEO of Immuneering?Immuneering's CEO is Benjamin J. Zeskind.
Is Immuneering publicly listed?Yes, Immuneering is a public company listed on Nasdaq.
What is the stock symbol of Immuneering?Immuneering trades under IMRX ticker.
When did Immuneering go public?Immuneering went public in 2021.
Who are competitors of Immuneering?Immuneering main competitors include Oryzon Genomics, Panacea Biotec, Prelude Therapeutics, IMBiologics, Santhera Pharma, Zentalis Pharma, Eledon Pharmaceuticals, Surrozen, SAB Bio, Organogenesis.
What is the current market cap of Immuneering?Immuneering's current market cap is $277M.
Is Immuneering profitable?No, Immuneering is not profitable.
What is the current net income of Immuneering?Immuneering's last 12 months net income is ($65M).
How many companies Immuneering has acquired to date?Immuneering hasn't acquired any companies yet (or none have been disclosed publicly).
In how many companies Immuneering has invested to date?Immuneering hasn't invested in any companies yet (or none have been disclosed publicly).

See public comps similar to Immuneering

Lists including Immuneering

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial